Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Calumet Specialty Products Partners Prices Public Offering - Quick Facts

RELATED NEWS
Trade CLMT now with 

Calumet Specialty Products Partners L.P. (CLMT: Quote) announced it priced an underwritten public offering of 5.25 million common units at $37.50 per unit. Calumet also granted the underwriters a 30-day option to purchase up to 787,500 additional common units.

Calumet intends to use the net proceeds, including a proportionate capital contribution from its general partner, for general partnership purposes, including working capital, capital expenditures, acquisitions and potentially the redemption or repurchase of outstanding notes.

The offering is expected to close on April 1, 2013.

Click here to receive FREE breaking news email alerts for Calumet Specialty Products Partners L.P. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving modestly higher in morning trading, stocks showed a substantial move to the downside over the course of the trading day on Wednesday. The major averages pulled back well off their highs for the session, sliding firmly into negative territory. Ebola "czar" Ron Kain is scheduled to meet with President Barack Obama on Wednesday as he begins his efforts to coordinate the government's response to the deadly disease. Klain, who previously served as chief of staff to Vice President Joe Biden and then-Vice President Al Gore, was named as Ebola Response Coordinator last Friday. Potentially complicating the outlook for control of the Senate, the results of a SurveyUSA poll conducted for WXIA-TV in Atlanta suggest that the Georgia Senate race between Republican David Perdue and Democrat Michelle Nunn could be headed for a runoff.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.